Insulin-like growth factor 1 receptor antibody induces rhabdomyosarcoma cell death via a process involving AKT and Bcl-x L

L. H. Mayeenuddin, Y. Yu, Z. Kang, Lee J. Helman, L. Cao

Research output: Contribution to journalArticle

Abstract

Insulin-like growth factors (IGFs) and their receptor, IGF-1 receptor (IGF1R), have important roles in growth, development, stress response, aging and cancer. There are many agents that inhibit IGF1R in oncology clinical development, and in some cases, they have been associated with rapid tumor regression. However, it is not clear by which process these targeted agents induce cancer cell death and how to predict such tumor responses. Here, we showed that IGF1R antibody led to rapid cell death and tumor regression in some rhabdomyosarcoma (RMS) cells. Mechanistic analysis revealed a rapid onset of mitochondrial-dependent apoptosis, including mitochondrial depolarization, cytochrome C release and the activation of specific caspases. The antibody sensitive cells had greater dependence on AKT for maintaining downstream signaling and the expression of a constitutively active AKT, which restored AKT-signaling in these cells, inhibited anti-IGF1R induced cell death. Further analysis showed IGF1R antibody-induced hypophosphorylation of BAD and activation of downstream BAX. Interestingly, the examination of RMS cell lines and tumors revealed an inverse correlation between elevated IGF1R and Bcl-2 level (P0.033), with the sensitive cells lacking Bcl-2 expression. The overexpression of BAD specific target, Bcl-x L, conferred resistance, whereas Bcl-x L knockdown sensitized cells lacking Bcl-2 to anti-IGF1R-induced cell death. We propose that RMS pathogenesis involves increased IGF1R expression that enhances AKT and Bcl-x L-mediated cell survival, and the blockage of IGF1R results in inhibition of survival signal from Bcl-x L and cell death in the sensitive Bcl-2 negative cells.

Original languageEnglish (US)
Pages (from-to)6367-6377
Number of pages11
JournalOncogene
Volume29
Issue number48
DOIs
StatePublished - Dec 2 2010
Externally publishedYes

Fingerprint

Somatomedin Receptors
IGF Type 1 Receptor
Rhabdomyosarcoma
Cell Death
Antibodies
Neoplasms
Medical Oncology
Cytochromes
Caspases
Tumor Cell Line
Growth and Development
Cell Survival
Apoptosis

Keywords

  • apoptosis
  • Bcl-2
  • Bcl-xL
  • IGF1R therapeutic antibody
  • predictive biomarker
  • tumor regression

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Insulin-like growth factor 1 receptor antibody induces rhabdomyosarcoma cell death via a process involving AKT and Bcl-x L. / Mayeenuddin, L. H.; Yu, Y.; Kang, Z.; Helman, Lee J.; Cao, L.

In: Oncogene, Vol. 29, No. 48, 02.12.2010, p. 6367-6377.

Research output: Contribution to journalArticle

Mayeenuddin, L. H. ; Yu, Y. ; Kang, Z. ; Helman, Lee J. ; Cao, L. / Insulin-like growth factor 1 receptor antibody induces rhabdomyosarcoma cell death via a process involving AKT and Bcl-x L. In: Oncogene. 2010 ; Vol. 29, No. 48. pp. 6367-6377.
@article{680e2902d3574235bbed88f00bd1b1ec,
title = "Insulin-like growth factor 1 receptor antibody induces rhabdomyosarcoma cell death via a process involving AKT and Bcl-x L",
abstract = "Insulin-like growth factors (IGFs) and their receptor, IGF-1 receptor (IGF1R), have important roles in growth, development, stress response, aging and cancer. There are many agents that inhibit IGF1R in oncology clinical development, and in some cases, they have been associated with rapid tumor regression. However, it is not clear by which process these targeted agents induce cancer cell death and how to predict such tumor responses. Here, we showed that IGF1R antibody led to rapid cell death and tumor regression in some rhabdomyosarcoma (RMS) cells. Mechanistic analysis revealed a rapid onset of mitochondrial-dependent apoptosis, including mitochondrial depolarization, cytochrome C release and the activation of specific caspases. The antibody sensitive cells had greater dependence on AKT for maintaining downstream signaling and the expression of a constitutively active AKT, which restored AKT-signaling in these cells, inhibited anti-IGF1R induced cell death. Further analysis showed IGF1R antibody-induced hypophosphorylation of BAD and activation of downstream BAX. Interestingly, the examination of RMS cell lines and tumors revealed an inverse correlation between elevated IGF1R and Bcl-2 level (P0.033), with the sensitive cells lacking Bcl-2 expression. The overexpression of BAD specific target, Bcl-x L, conferred resistance, whereas Bcl-x L knockdown sensitized cells lacking Bcl-2 to anti-IGF1R-induced cell death. We propose that RMS pathogenesis involves increased IGF1R expression that enhances AKT and Bcl-x L-mediated cell survival, and the blockage of IGF1R results in inhibition of survival signal from Bcl-x L and cell death in the sensitive Bcl-2 negative cells.",
keywords = "apoptosis, Bcl-2, Bcl-xL, IGF1R therapeutic antibody, predictive biomarker, tumor regression",
author = "Mayeenuddin, {L. H.} and Y. Yu and Z. Kang and Helman, {Lee J.} and L. Cao",
year = "2010",
month = "12",
day = "2",
doi = "10.1038/onc.2010.364",
language = "English (US)",
volume = "29",
pages = "6367--6377",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "48",

}

TY - JOUR

T1 - Insulin-like growth factor 1 receptor antibody induces rhabdomyosarcoma cell death via a process involving AKT and Bcl-x L

AU - Mayeenuddin, L. H.

AU - Yu, Y.

AU - Kang, Z.

AU - Helman, Lee J.

AU - Cao, L.

PY - 2010/12/2

Y1 - 2010/12/2

N2 - Insulin-like growth factors (IGFs) and their receptor, IGF-1 receptor (IGF1R), have important roles in growth, development, stress response, aging and cancer. There are many agents that inhibit IGF1R in oncology clinical development, and in some cases, they have been associated with rapid tumor regression. However, it is not clear by which process these targeted agents induce cancer cell death and how to predict such tumor responses. Here, we showed that IGF1R antibody led to rapid cell death and tumor regression in some rhabdomyosarcoma (RMS) cells. Mechanistic analysis revealed a rapid onset of mitochondrial-dependent apoptosis, including mitochondrial depolarization, cytochrome C release and the activation of specific caspases. The antibody sensitive cells had greater dependence on AKT for maintaining downstream signaling and the expression of a constitutively active AKT, which restored AKT-signaling in these cells, inhibited anti-IGF1R induced cell death. Further analysis showed IGF1R antibody-induced hypophosphorylation of BAD and activation of downstream BAX. Interestingly, the examination of RMS cell lines and tumors revealed an inverse correlation between elevated IGF1R and Bcl-2 level (P0.033), with the sensitive cells lacking Bcl-2 expression. The overexpression of BAD specific target, Bcl-x L, conferred resistance, whereas Bcl-x L knockdown sensitized cells lacking Bcl-2 to anti-IGF1R-induced cell death. We propose that RMS pathogenesis involves increased IGF1R expression that enhances AKT and Bcl-x L-mediated cell survival, and the blockage of IGF1R results in inhibition of survival signal from Bcl-x L and cell death in the sensitive Bcl-2 negative cells.

AB - Insulin-like growth factors (IGFs) and their receptor, IGF-1 receptor (IGF1R), have important roles in growth, development, stress response, aging and cancer. There are many agents that inhibit IGF1R in oncology clinical development, and in some cases, they have been associated with rapid tumor regression. However, it is not clear by which process these targeted agents induce cancer cell death and how to predict such tumor responses. Here, we showed that IGF1R antibody led to rapid cell death and tumor regression in some rhabdomyosarcoma (RMS) cells. Mechanistic analysis revealed a rapid onset of mitochondrial-dependent apoptosis, including mitochondrial depolarization, cytochrome C release and the activation of specific caspases. The antibody sensitive cells had greater dependence on AKT for maintaining downstream signaling and the expression of a constitutively active AKT, which restored AKT-signaling in these cells, inhibited anti-IGF1R induced cell death. Further analysis showed IGF1R antibody-induced hypophosphorylation of BAD and activation of downstream BAX. Interestingly, the examination of RMS cell lines and tumors revealed an inverse correlation between elevated IGF1R and Bcl-2 level (P0.033), with the sensitive cells lacking Bcl-2 expression. The overexpression of BAD specific target, Bcl-x L, conferred resistance, whereas Bcl-x L knockdown sensitized cells lacking Bcl-2 to anti-IGF1R-induced cell death. We propose that RMS pathogenesis involves increased IGF1R expression that enhances AKT and Bcl-x L-mediated cell survival, and the blockage of IGF1R results in inhibition of survival signal from Bcl-x L and cell death in the sensitive Bcl-2 negative cells.

KW - apoptosis

KW - Bcl-2

KW - Bcl-xL

KW - IGF1R therapeutic antibody

KW - predictive biomarker

KW - tumor regression

UR - http://www.scopus.com/inward/record.url?scp=78649846572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649846572&partnerID=8YFLogxK

U2 - 10.1038/onc.2010.364

DO - 10.1038/onc.2010.364

M3 - Article

VL - 29

SP - 6367

EP - 6377

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 48

ER -